Orexo AB
STO:ORX

Watchlist Manager
Orexo AB Logo
Orexo AB
STO:ORX
Watchlist
Price: 19.08 SEK -3.25%
Market Cap: 662.3m SEK

EV/EBIT
Enterprise Value to EBIT

-7.1
Current
-4.9
Median
15.7
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-7.1
=
Enterprise Value
1B SEK
/
EBIT
-140.8m SEK
Market Cap EV/EBIT
SE
Orexo AB
STO:ORX
658.4m SEK -7.1
US
Eli Lilly and Co
NYSE:LLY
730.4B USD 38.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 17 702.3
US
Johnson & Johnson
NYSE:JNJ
364B USD 16
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 15.4
CH
Roche Holding AG
SIX:ROG
209B CHF 11.1
CH
Novartis AG
SIX:NOVN
186.9B CHF 14.1
UK
AstraZeneca PLC
LSE:AZN
161.1B GBP 197.1
US
Merck & Co Inc
NYSE:MRK
201.7B USD 10.4
IE
Endo International PLC
LSE:0Y5F
163.5B USD 655.3
US
Pfizer Inc
NYSE:PFE
136.6B USD 10.5
EBIT Growth EV/EBIT to Growth
SE
Orexo AB
STO:ORX
Average EV/EBIT: 1 867.1
Negative Multiple: -7.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.6
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
15.4
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.1
6%
1.8
CH
Novartis AG
SIX:NOVN
14.1
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.1
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.4
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.5
10%
1

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-33.4
2-Years Forward
EV/EBIT
-26.4
3-Years Forward
EV/EBIT
-62.9